Scarica l'app Stockscreener
0.1095
9.50%
0.0095
Pre-mercato:
.11
0.0005
+0.46%
Calidi Biotherapeutics Inc Borsa (CLDI) Ultime notizie
Calidi Biotherapeutics Inc (CLDI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Calidi highlights new EpCam-targeting T-cell engager data - Stock Titan
Calidi Biotherapeutics Inc (CLDI) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Calidi Biotherapeutics Inc (CLDI) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Calidi Biotherapeutics Inc (CLDI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Calidi Biotherapeutics Inc (CLDI) Cash Flow - TradingKey
Stock Splits Calendar for: - Yahoo! Finance Canada
TradingKey - TradingKey
Calidi Biotherapeutics Inc (CLDI) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Calidi Biotherapeutics, Inc. (CLDI) stock price, news, quote and history - Yahoo Finance UK
Calidi Biotherapeutics To Carry Out 1-for-16 Reverse Stock Split On July 31st, 2026 - Moomoo
Calidi Gains on Company Update - Baystreet.ca
Calidi Biotherapeutics Provides Mid-Year Corporate Update and Future Key Value Drivers - GlobeNewswire
Why Crown Holdings Shares Are Trading Higher; Here Are 20 Stocks Moving Premarket - Sahm
Calidi Biotherapeutics to Effect 1-for-16 Reverse Stock Split - marketscreener.com
Calidi Announces Reverse Stk Split, Expected to Begin Trading on a 1-For-16 Split Adjusted Basis on July 31 - Moomoo
Calidi shareholders will get one share for every 16 held - Stock Titan
Calidi Announces Reverse Stock Split, Expected to Begin Trading on a 1-for-16 Split Adjusted Basis on July 31, 2026 - Sahm
Calidi Biotherapeutics Plans Relocation Through New Lease Agreements - TipRanks
Calidi Biotherapeutics Signs 44-Month Lease at 5580 Morehouse Drive, San Diego for New Corporate Headquarters - Minichart
New lease could save Calidi Biotherapeutics (NYSE American: CLDI) $1.1M yearly - Stock Titan
Calidi Biotherapeutics Reports Inducement Grant Under NYSE American LLC Company Guide Section 711 - The Manila Times
Calidi lures new finance chief with 100,000 stock options - Stock Titan
Calidi Biotherapeutics (CLDI) stock plunges 35% after hours — here's why - MSN
CLDI Q4 2025 Earnings: Surprise EPS Beat Signals Cost Discipline Amid Pre-Revenue PhaseTech Earnings Analysis - dars.gov.et
CLDI Q4 2025 Earnings: Narrower-Than-Expected Loss Fails to Lift SharesRevenue Growth Report - dars.gov.et
Calidi Biotherapeutics (CLDI) director Sanders Corazon files initial Form 3 - Stock Titan
CLDI Q4 2025 Earnings: EPS Surprises with 73.6% Beat as Clinical Pipeline AdvancesAnalyst Consensus Shift - dars.gov.et
CLDI Q4 2025 Earnings: Narrower-than-expected loss boosts shares by 8.88%Low Growth Earnings - dars.gov.et
Calidi Biotherapeutics, Inc. Actuals & Estimates (AMEX:CLDI) - TradingView
Calidi Biotherapeutics Presents New Data on CLD-501, Its In Situ T-Cell Engager Candidate Targeting TROP-2 at the T-Cell Engager Therapeutic Summit - Sahm
Calidi’s tumor-targeted T-cell approach aims at hard-to-hit solid tumors - Stock Titan
Calidi Biotherapeutics unveils promising data o... - Pluang
Form 8K Calidi Biotherapeutics Inc For: 23 June By Investing.com - Investing.com Australia
Form 8K Calidi Biotherapeutics Inc For: 23 June - Investing.com UK
Calidi Biotherapeutics Expands Board With New Independent Director - TipRanks
Calidi Biotherapeutics Appoints Industry Veteran Corsee Sanders, Ph.D., to Board of Directors to Advance RedTail Platform and CLD-401 Clinical Development – Minichart - Minichart
Calidi Biotherapeutics appoints Corsee Sanders to board - Investing.com
Industry veteran Corsee Sanders joins Calidi Biotherapeutics (CLDI) board and Audit Committee - Stock Titan
Calidi Biotherapeutics appoints Corsee Sanders to board By Investing.com - Investing.com UK
Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors - The Manila Times
Press Release: Calidi Biotherapeutics Appoints Former Genentech/Roche and Celgene Executive Corsee Sanders, Ph.D., to Board of Directors - Moomoo
Calidi Biotherapeutics Appoints Former Genentech/Roche and - GlobeNewswire
Calidi adds former Genentech and Roche executive to board - Stock Titan
Calidi Biotherapeutics Inc (CLDI) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Calidi Biotherapeutics (CLDI) Surges 11%: Micro-Cap Biotech Tests Key Resistance at $0.18PCR Spike - dars.gov.et
Calidi Biotherapeutics, Inc. Files Form 8-K with SEC: Key Corporate Details, Stock Info & NYSE American Listing - Minichart
CLDI News | CALIDI BIOTHERAPEUTICS INC (NYSEARCA:CLDI) - ChartMill
Calidi Biotherapeutics Stockholders Approve Key Governance Measures - TipRanks
Calidi Biotherapeutics (CLDI) stockholders back all proposals at 2026 annual meeting - Stock Titan
Calidi Biotherapeutics Inc (CLDI) Valuation: PE, PB & Fair Value Analysis - TradingKey
Calidi Biotherapeutics Inc (CLDI) Institutional Confidence - TradingKey
Calidi Biotherapeutics Inc (CLDI) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Calidi receives pre-IND feedback from FDA on CLD-401 - BioWorld News
Calidi Biotherapeutics Receives Positive Feedback From FDA for CLD-401 Pre-IND Application - marketscreener.com
Calidi Biotherapeutics Receives Positive Pre-IND Feedback from US FDA for CLD-401 Indicating Agreement on its Current Development Strategy as it Advances Towards a First-in-Human Study - GlobeNewswire
CALIDI BIOTHERAPEUTICS INC (CLDI) Stock Chart - ChartMill
1.97%
0.83%
Capitalizzazione:
|
Volume (24 ore):